How NVIDIA grew with the healthcare market instead of pushing into it
Pharmaceutical Technology
JULY 22, 2024
As the use of AI soared across healthcare, NVIDIA fit the bill in providing the necessary technology – and its stock tells the same story.
Mon.Jul 22, 2024
344 
Ionis plots next steps for Angelman drug Biogen passed on
Bio Pharma Dive
JULY 22, 2024
The company plans to start a late-stage study next year, after a smaller trial found its drug offered “robust and consistent” benefits on communication, cognition and motor function.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
How NIVIDIA grew with the healthcare market instead of pushing into it
Pharmaceutical Technology
JULY 22, 2024
As the use of AI soared across healthcare, NVIDIA fit the bill in providing the necessary technology – and its stock tells the same story.
Breakthroughs in immunotherapy: glycoproteins as predictive biomarkers for therapeutic response
Bio Pharma Dive
JULY 22, 2024
Serum-based glycoproteins demonstrate success in predicting immune checkpoint inhibitor therapy outcomes.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
EMA accepts GSK’s Blenrep MAA for multiple myeloma for review
Pharmaceutical Technology
JULY 22, 2024
The EMA has accepted for review GSK’s MAA for Blenrep for relapsed or refractory multiple myeloma (r/r MM).
Private biotech M&A surges amid difficult IPO market
Bio Pharma Dive
JULY 22, 2024
Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
J&J seeks expanded approval for antidepressant Spravato
Bio Pharma Dive
JULY 22, 2024
The company is seeking a monotherapy approval for Spravato, sales of which have climbed in recent quarters.
Pharma exports report 9.3% growth in Q1, FY25
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 22, 2024
Exports of drugs and pharmaceuticals from the country registered a 9.3 per cent growth in the first three months of the fiscal year from April to June, 2024, while imports reported a jump of 12.4 per cent, compared to the corresponding quarter of previous year. The exports during the three months stood at $7.
US government declines to clear Bluebird fertility support for Zynteglo patients
Bio Pharma Dive
JULY 22, 2024
The Health and Human Services' inspector general issued a "negative opinion" on Bluebird's request one week after Vertex sued the federal government over access to fertility preservation services.
New study shows wearable trackers provide clinical use for heart disease patients
Pharma Times
JULY 22, 2024
Cardiovascular disease, including coronary heart disease, currently affects around seven million people in the UK
Clinical data registries: Transforming the future of medical research
Bio Pharma Dive
JULY 22, 2024
Clinical data registries have become invaluable for generating unique insights for life sciences. Read on to learn more.
UNAIDS boss calls on Gilead to provide ‘miracle’ drug to developing countries
Pharmaceutical Technology
JULY 22, 2024
UNAIDS executive director Winnie Byanyima called upon Gilead to allow generics to be made of lenacapavir now.
Going from Zero to 100: Generating Evidence through Pragmatic Research to Address the Pressing (July 2024)
Rethinking Clinical Trials
JULY 22, 2024
July 15-16, 2024 : The NIH Pragmatic Trials Collaboratory hosted a Workshop at the 2023 AcademyHealth 16th Annual Conference on the Science of Dissemination and Implementation in Health. This training workshop introduces concepts in the design, conduct, and implementation of embedded pragmatic clinical trials (ePCTs), and provides firsthand ePCT experiences and case studies from the NIH Pragmatic Trials Collaboratory Trials.
Altamira’s drug-delivering nanoparticles could treat AAA
Pharmaceutical Technology
JULY 22, 2024
The SOD2 mRNA delivered with SemaPhore technology showed improved survival rates for mice with abdominal aortic aneurysm.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Sinking prices for generic meds a major factor in US shortage crisis: report
Fierce Pharma
JULY 22, 2024
As lawmakers and industry groups seek to get a handle on U.S. | As lawmakers and industry groups seek to get a handle on U.S. drug shortages, a new white paper from German market analytics firm QYOBO supports the thesis that disproportionately low prices for generic medicines can make it difficult for drugmakers to keep supplies afloat.
Ilumetri and Ebglyss spur Almirall’s growth in dermatology
Pharmaceutical Technology
JULY 22, 2024
Shares in the company opened 3.9% higher buoyed by an H1 performance in line with expectations.
Agilent Technologies lays out $925M to acquire Canadian specialty CDMO Biovectra
Fierce Pharma
JULY 22, 2024
After changing hands several times throughout the 2010s, Canadian specialty contract development and manufacturing organization (CDMO) Biovectra has agreed to fly the Agilent flag. | Agilent has revealed that it’s signed a definitive agreement to acquire Biovectra for $925 million through a mix of cash and debt financing. The deal is expected to close this year.
Navigating the challenges of bringing cell and gene therapies to market
Pharmaceutical Technology
JULY 22, 2024
Understanding of cell therapies is rapidly improving, but there remain significant challenges in getting new therapies onto the market.
Trial investigates faecal microbiota transplantation to treat rare liver disease
Pharma Times
JULY 22, 2024
Primary sclerosing cholangitis is estimated to affect one in 100,000 people worldwide annually
SIGA scores HHS contract for smallpox vaccine Tpoxx worth $113m
Pharmaceutical Technology
JULY 22, 2024
The company’s Tpoxx vaccine is used to treat orthopoxvirus but is only approved for treating smallpox by the US FDA.
Applying intercultural intelligence to promote growth in the Middle East
pharmaphorum
JULY 22, 2024
Learn how applying intercultural intelligence can promote growth and success in the dynamic and diverse business environment of the Middle East. Gain insights and strategies for effective cross-cultural communication and collaboration.
GRO Biosciences secures Series B funding for gout treatment
Pharmaceutical Technology
JULY 22, 2024
GRO Biosciences has secured $60.3m in a Series B financing round to progress the clinical development of its lead programme for gout.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Study points to route for 'one and done' flu vaccine
pharmaphorum
JULY 22, 2024
Scientists at OHSU in the US have developed a universal form of influenza vaccine that they say could protect against all strains of the virus
UK NICE recommends Accord’s Relugolix for prostate cancer
Pharmaceutical Technology
JULY 22, 2024
The UK NICE has recommended Accord's Relugolix as a treatment for advanced hormone-sensitive prostate cancer in its final draft guidance.
Rare Disease Diagnostics: Advancing Orphan Drug Development through Precision Testing
pharmaphorum
JULY 22, 2024
Rare Disease Diagnostics: Advancing Orphan Drug Development through Precision Testing Mike.
Astellas and Osaka University to develop cell therapy
Pharmaceutical Technology
JULY 22, 2024
Astellas Pharma subsidiaries and Osaka University in Japan link to develop pluripotent stem cell-derived cartilage organoid cell therapy.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
President Biden touts drug pricing achievements as he steps down from re-election campaign
Fierce Pharma
JULY 22, 2024
At his vacation home in Delaware, President Joe Biden made the striking announcement that he is dropping out of the 2024 | While President Joe Biden is officially out for the 2024 election, his term has certainly made a mark in the healthcare realm.
UK MHRA approves Lupin and Zentiva’s raltegravir for HIV
Pharmaceutical Technology
JULY 22, 2024
The UK MHRA has granted approval for the use of Lupin Healthcare and Zentiva Pharma’s generic raltegravir medicines for treating HIV.
Study finds wearables deliver key insights in heart disease
pharmaphorum
JULY 22, 2024
Consumer wearables have shown a benefit when used to monitor treatment responses in patients with atrial fibrillation and heart failure.
Bluebird bio's gene therapy fertility support program gets thumbs down from HHS inspector general
Fierce Pharma
JULY 22, 2024
The door is closing on bluebird bio’s attempt to secure Medicaid coverage for its fertility support program, which is already offered to patients with commercial insurance who receive its gene ther | The door is closing on bluebird bio’s attempt to secure Medicaid coverage for its fertility support program, which is already offered to patients with commercial insurance who receive its gene therapies.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content